Third-quarter events to watch for large drug makers

As the second quarter comes to a close Evaluate Vantage delves into non-Covid-19-related catalysts due next quarter for large drug makers. One of the most keenly awaited events is not clinical data but a filing for Biogen’s Alzheimer’s projecr aducanumab. Biogen had previously guided to a submission earlier in the year, but a delay announced in April saw shares fall over 9%.